Jingyu Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingyu Zhao has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Renal Division, Peking University First Hospital, Beijing, China
2 shared publications - Peien Han
Department of Health Policy and Management School of Public Health Peking University Beijing China
2 shared publications - Xia Wei
Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK
2 shared publications - Yaqun Fu
Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China
2 shared publications Jiawei Zhang
Department of Health Policy and Management School of Public Health Peking University Beijing China
1 shared publicationLiming Li
Department of Epidemiology and Health Statistics School of Public Health Peking University Beijing China
1 shared publication
Latest Publications
- Open Access
- 26 April 2023
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 16 (2) , 152-165
Cost‐effectiveness of COVID‐19 vaccination: A systematic review
Objective: The COVID‐19 vaccination strategy has been widely used to protect population health worldwide. This study aims to summarize the cost‐effectiveness evidence of economic evaluation of COVID‐19 vaccination strategies to provide evidence supporting the usage of COVID‐19 vaccination, especially where the supply of COVID‐19 vaccine is limited.Methods: A systematic literature review was performed by searching both English and Chinese databases, including PubMed, Embase, Science Direct, Web of Science, Medline, Scopus, and CNKI. Articles published from January 1, 2020 to August 1, 2022 (PROSPERO registration number: CRD42022355442).Results: Of the 1035 papers identified, a total of 28 English studies that met the preset criteria were included. COVID‐19 vaccination and booster vaccination were cost‐effective or cost‐saving regardless of the vaccine type; vaccine efficacy, vaccine price, vaccine supply or prioritization, and vaccination pace were the influential factors of cost‐effectiveness among different population groups. When supply is adequate, mass vaccination should be encouraged, while when supply is inadequate, prioritizing the high risk and the elderly is more cost‐effective.Conclusions: COVID‐19 vaccination strategies are economically favorable in a wide range of countries and population groups, and further research on suitable strategies for booster COVID‐19 vaccination is needed.
- 26 April 2023
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 16 (2) , 152-165
Open AccessCost‐effectiveness of COVID‐19 vaccination: A systematic review
Objective: The COVID‐19 vaccination strategy has been widely used to protect population health worldwide. This study aims to summarize the cost‐effectiveness evidence of economic evaluation of COVID‐19 vaccination strategies to provide evidence supporting the usage of COVID‐19 vaccination, especially where the supply of COVID‐19 vaccine is limited.Methods: A systematic literature review was performed by searching both English and Chinese databases, including PubMed, Embase, Science Direct, Web of Science, Medline, Scopus, and CNKI. Articles published from January 1, 2020 to August 1, 2022 (PROSPERO registration number: CRD42022355442).Results: Of the 1035 papers identified, a total of 28 English studies that met the preset criteria were included. COVID‐19 vaccination and booster vaccination were cost‐effective or cost‐saving regardless of the vaccine type; vaccine efficacy, vaccine price, vaccine supply or prioritization, and vaccination pace were the influential factors of cost‐effectiveness among different population groups. When supply is adequate, mass vaccination should be encouraged, while when supply is inadequate, prioritizing the high risk and the elderly is more cost‐effective.Conclusions: COVID‐19 vaccination strategies are economically favorable in a wide range of countries and population groups, and further research on suitable strategies for booster COVID‐19 vaccination is needed.
- Open Access
- 19 July 2022
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 917732
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
Objective: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence.Methods: Through a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results.Results: A total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective.Conclusion: Inactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China.
- 19 July 2022
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 917732
Open AccessEffectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
Objective: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence.Methods: Through a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results.Results: A total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective.Conclusion: Inactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China.